Skip to main content

Table 2 List of pathways in which the genes are included. In bold the genes resulting upregulated upon GSK0660 treatment

From: Neuroprotective effects of the PPARβ/δ antagonist GSK0660 in in vitro and in vivo Parkinson’s disease models

Parkin complex

PARK7

Parkin substrate

GPR37

Cell adhesion

NFASC

Ubiquitination

FBXO9, LRRK2, PARK2, PINK1, UBA1, UCHL1

Inflammation

PRDX2

Apoptosis

MAPK9, BDNF, OPA1, PRDX2

Mitochondria

LRRK2, OPA1, PARK7, PINK1, SNCA, UCHL1, VDAC3

Synaptic vesicles

LRRK2

Signal transduction

Dopaminergic: NSG1, DDC, PARK2, PARK7, PINK1, SNCA

MAP Kinase: MAPK9, PRDX2

Ion transport

ATP2B2, CXXC1, SNCA, VDAC3

Transporters

VDAC3

BDNF pathway

BDNF, NTRK2 (TrkB), CREB1

Others

NCOA1, RTN1